2015 Press Releases

2015 Press Releases

2017 | 2016 | 2015
  • Dec 21, 2015 

    Novavax Appoints Mark Twyman Vice President Marketing - 

    GAITHERSBURG, Md., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Mark Twyman to the position of Vice President, Marketing. Mr. Twyman’s efforts will be focused on the commercial launch of the company’s RSV F Vaccine. Mr. Twyman joins Novavax with more than 20 years of experience commercializing he... More >>

  • Dec 14, 2015 

    Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults - 

    GAITHERSBURG, Md., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced complete target enrollment of the pivotal Phase 3 clinical trial, known as Resolve™, of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older). The Resolve trial is a randomi... More >>

  • Dec 08, 2015 

    Novavax to Participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference - 

    GAITHERSBURG, Md., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference. Conference details are as follows: Date: Tuesday, December 15, 2015 Forum: One-on-one meetings Location: The Langham Boston, Boston, MA About Nov... More >>

  • Dec 03, 2015 

    Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization - 

    GAITHERSBURG, Md., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the enrollment of the first participant in a global pivotal Phase 3 clinical trial, known as Prepare™, of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in healthy pregnant women. The Prepare trial is a randomi... More >>

  • Nov 24, 2015 

    Novavax to Present at the 27th Annual Piper Jaffray Healthcare Conference - 

    GAITHERSBURG, Md., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 27th Annual Piper Jaffray Healthcare Conference. Conference details are as follows: Date: Tuesday, December 1, 2015 Time: 2:00 p.m. U.S. Eastern Time Location: New York Palace Hotel, New Y... More >>

  • Nov 16, 2015 

    Novavax to Make Multiple Presentations at RSV Vaccines for the World - 

    Conference Will Take Place November 18-20, 2015 in La Jolla, California GAITHERSBURG, Md., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Novavax representatives will be making multiple oral presentations at the RSV Vaccines for the World conference, November 18-20, 2015 in La Jolla, California. Poster, present... More >>

  • Nov 10, 2015 

    Novavax to Present at the Stifel 2015 Healthcare Conference - 

    GAITHERSBURG, Md., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Barclay “Buck” Phillips, SVP, Chief Financial Officer and Treasurer, will present at the Stifel 2015 Healthcare Conference. Conference details are as follows: Date: Tuesday, November 17, 2015 Time: 4:30 p.m. US Eastern Time Location: New York P... More >>

  • Nov 09, 2015 

    Novavax Reports Third Quarter 2015 Financial Results - 

    GAITHERSBURG, Md., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the third quarter and nine months ended September 30, 2015. Novavax Third Quarter and Subsequent Achievements Announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle va... More >>

  • Nov 09, 2015 

    Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults - 

    GAITHERSBURG, Md., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the initiation of a Phase 3 clinical trial, known as Resolve™, of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older). The Resolve trial is a randomized, observer-blinded,... More >>

  • Nov 02, 2015 

    Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2015 - 

    GAITHERSBURG, Md., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its third quarter 2015 financial and operating results before the open of U.S. financial markets on Monday, November 9, 2015. In addition, management will host a conference call to discuss the quarterly results and provide an update on c... More >>

  • Oct 22, 2015 

    Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults - 

    GAITHERSBURG, Md. , Oct. 22, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 rollover clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults enrolled in the prior Phase 2 trial. The trial is a randomized, ob... More >>

  • Oct 01, 2015 

    Novavax Announces Management Promotion - 

    GAITHERSBURG, Md., Oct. 01, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Jody Lichaa has been named Vice President, Quality Assurance. Ms. Lichaa joined Novavax as the Executive Director, Quality Assurance in October 2011. She is responsible for providing strategy, oversight, and direction of the Company’s quality assuran... More >>

  • Sep 29, 2015 

    Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics - 

    Novavax’ Fifth Positive Top-Line Clinical Trial Announcement of the 3rd Quarter GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in healthy children. The trial was a ... More >>

  • Sep 29, 2015 

    Novavax to Host 3rd Annual Analyst and Investor Meeting - 

    GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, will host its 3rd annual Analyst and Investor Meeting today, Tuesday, September 29, 2015 from 9:00 a.m. – 11:00 a.m. ET in New York, NY. Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongoing clinical develo... More >>

  • Sep 29, 2015 

    Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization - 

    -RSV F Vaccine was safe and well-tolerated -Significant anti-F, PCA and microneutralizing antibody responses elicited in mothers -Efficient antibody transfer from mothers to infants observed -Results suggest potential to protect infants when they are most at risk GAITHERSBURG, Md., Sept. 29, 2015 /PRNewswire/ -- Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvant... More >>

  • Sep 29, 2015 

    Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization - 

    Bill & Melinda Gates Foundation to Support Development of the RSV F Vaccine Program GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it has been awarded a grant of up to $89 million from the Bill & Melinda Gates Foundation to support development of the RSV F Vaccine Phase 3 clinical trial in p... More >>

  • Sep 21, 2015 

    Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference - 

    GAITHERSBURG, Md., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the Ladenburg Thalmann Healthcare 2015 Conference. Conference details are as follows: Date: Tuesday, September 29, 2015 Time: 1:30 – 1:55 p.m. US Eastern Time Location: Sofitel Hotel, New Yor... More >>

  • Sep 15, 2015 

    Novavax RSV F Vaccine is Highly Immunogenic With Robust Transplacental Antibody Transfer in Preclinical Maternal Immunization Model - 

    GAITHERSBURG, Md., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) was shown to be highly immunogenic in a guinea pig model of maternal immunization. The preclinical study was published in the journal Vaccine.1 Direct immunization of infants... More >>

  • Sep 10, 2015 

    Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease - 

    GAITHERSBURG, Md., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the full data set from its clinical trial of the RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of childbearing age (18-35 years) were published in the Journal of Infectious Disease. The Company previously announce... More >>

  • Sep 02, 2015 

    Novavax to Participate in Multiple Investor Conferences in September - 

    GAITHERSBURG, Md., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the Company will participate in the FBR 2nd Annual Healthcare Conference and the Citi 10th Annual Biotech Conference. Conference details are as follows: FBR 2nd Annual Healthcare Conference Date: Wednesday, September 9, 2015 Forum: One-on-one meet... More >>

  • Aug 26, 2015 

    Novavax to Host 3rd Annual Analyst and Investor Meeting - 

    GAITHERSBURG, Md., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it will host its 3rd annual Analyst and Investor Meeting on Tuesday, September 29, 2015 from 9:00 a.m. – 11:00 a.m. ET in New York, NY. Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongo... More >>

  • Aug 10, 2015 

    Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults - 

    - First respiratory syncytial virus (RSV) vaccine to demonstrate efficacy in any population - Statistically significant vaccine efficacy in prevention of symptomatic RSV disease in older adults - Large prospective epidemiological study of RSV; detected a seasonal attack rate of 4.9% for symptomatic RSV disease GAITHERSBURG, Md., Aug. 10, 2015 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization ... More >>

  • Aug 10, 2015 

    Novavax Reports Second Quarter 2015 Financial Results - 

    GAITHERSBURG, Md., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the second quarter and six months ended June 30, 2015. Novavax Second Quarter and Subsequent Achievements: Announced positive top-line data from a Phase 2 trial of its RSV F-protein nanoparticle vaccine candidate (RSV F V... More >>

  • Aug 05, 2015 

    Novavax to Present at the Wedbush PacGrow Healthcare Conference - 

    GAITHERSBURG, Md., Aug. 05, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the Wedbush PacGrow Healthcare Conference. Conference details are as follows: Date: Wednesday, August 12, 2015 Time: 12:45 p.m. US Eastern Time Location: Le Parker Meridian hotel, New York Ci... More >>

  • Aug 03, 2015 

    Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 10, 2015 - 

    GAITHERSBURG, Md., Aug. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 2015 financial and operating results after the close of U.S. financial markets on Monday, August 10, 2015. In addition, management will host a conference call to discuss the quarterly results and provide an update on c... More >>

  • Jul 30, 2015 

    Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP - 

    GAITHERSBURG, Md., July 30, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 2 clinical trial of its recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate (Seasonal Influenza VLP). This project has been funded in whole or in part with Federal funds from the Offi... More >>

  • Jul 21, 2015 

    Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference - 

    GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™ as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical ... More >>

  • Jun 19, 2015 

    Novavax Recognized by Washington Post as Top Workplace - 

    GAITHERSBURG, Md., June 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that, for the second consecutive year, it has been recognized as a Top Workplace for 2015. “This recognition is a testament to the passion and dedication of our 350 SuperNovas,” said Stanley C. Erck, President and CEO. “Our employees exemplify the excell... More >>

  • Jun 18, 2015 

    Novavax Appoints Gail Boudreaux to Board - 

    GAITHERSBURG, Md., June 18, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Gail K. Boudreaux to its Board of Directors. “We are delighted to welcome Gail to Novavax’ Board,” said Stanley C. Erck, President and CEO of Novavax. “Her outstanding leadership and business experience will be important to our conti... More >>

  • Jun 15, 2015 

    Novavax Announces Management Promotion - 

    GAITHERSBURG, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Chris Dunne has been named Vice President, Finance. Mr. Dunne joined Novavax as the Executive Director, Finance in January 2010, with responsibility for financial reporting.  Prior to joining Novavax, he was Senior Director, Finance at Ore Pharmaceut... More >>

  • May 07, 2015 

    Novavax Reports First Quarter 2015 Financial Results - 

    GAITHERSBURG, Md., May 7, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the first quarter 2015. Corporate Highlights First Quarter and Subsequent Achievements: RSV Completed enrollment of two ongoing clinical trials of its RSV F Vaccine, including a Phase 2 study in elderly adults (60 years of ag... More >>

  • Apr 30, 2015 

    Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015 - 

    GAITHERSBURG, Md., April 30, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2015 financial and operating results after the close of U.S. financial markets on Thursday, May 7, 2015. In addition, management will host a conference call to discuss the quarterly results and provide an update on corp... More >>

  • Apr 08, 2015 

    Novavax to Present at the 14th Annual Needham Healthcare Conference - 

    GAITHERSBURG, Md., April 8, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference at 8:00 a.m. ET, April 15, 2015 in New York City at the Westin Grand Central Hotel. A live webcast link for the presentation will be av... More >>

  • Mar 31, 2015 

    Novavax Announces Closing of Public Offering - 

    GAITHERSBURG, Md., March 31, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the closing of the underwritten public offering priced on Wednesday, March 25, 2015. The company issued 27,758,620 shares of its common stock, including 3,620,689 shares pursuant to the underwriters' option to purchase additional shares. The shares wer... More >>

  • Mar 28, 2015 

    Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium on Filoviruses - 

    GAITHERSBURG, Md., March 28, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Gale Smith, Ph.D., Vice President, Vaccine Development, will present, "Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells," at the 7th International Symposium on Filoviruses, Saturday, March 28, 2015 at 10:15 a.m. a... More >>

  • Mar 26, 2015 

    Novavax Prices Public Offering of Common Stock - 

    GAITHERSBURG, Md., March 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it has priced an underwritten public offering of 24,137,931 shares of common stock at a price to the public of $7.25 per share for gross proceeds of approximately $175 million. Novavax expects to receive net proceeds, after deducting the underwriting ... More >>

  • Mar 24, 2015 

    Novavax Announces Proposed Public Offering of Common Stock - 

    GAITHERSBURG, Md., March 24, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer to sell, subject to market and other conditions, $175 million of its common stock in an underwritten public offering. As part of this offering Novavax intends to grant the underwriters a 30-day option to purchase up to an additiona... More >>

  • Mar 10, 2015 

    Novavax Appoints Brian Rosen as Vice President, Government Affairs - 

    GAITHERSBURG, Md., March 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen's effort... More >>

  • Feb 26, 2015 

    Novavax Reports Fourth Quarter and Year-End 2014 Financial Results - 

    GAITHERSBURG, Md., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the fourth quarter and twelve months ended December 31, 2014. Corporate Highlights Fourth Quarter and Subsequent Achievements: RSV Initiated a Phase 2 clinical trial of its RSV F-Protein nanoparticle vaccine can... More >>

  • Feb 19, 2015 

    Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015 - 

    GAITHERSBURG, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2014 financial and operating results after the close of U.S. financial markets on Thursday, February 26, 2015. In addition, management will host a conference call to discuss the quarterly and year-end fina... More >>

  • Feb 12, 2015 

    Novavax Announces Initiation of Ebola Vaccine Phase 1 Clinical Trial Supported by Non-Human Primate Challenge Data and Documented Rapid Manufacturing Capabilities - 

    Initiation of Enrollment of Phase 1 Clinical Trial of Ebola GP Vaccine   Non-Human Primate Challenge Data Signal Breakthrough in Ebola Vaccine Development   Rapid Manufacturing Process of Ebola GP Vaccine Published in BioProcessing Journal GAITHERSBURG, Md., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, ... More >>

  • Jan 08, 2015 

    Novavax Announces Management Promotion - 

    GAITHERSBURG, Md., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that Jill Hoyt has been named Vice President, Human Resources & Administration. Ms. Hoyt joined Novavax in February 2008 as Executive Director, Human Resources & Administration and has been instrumental in the successful growth of the company. Prior to joining Novavax, Ms. Hoyt held management positions of increasing responsibility in a number of companies, including 3e Technologies Internatio... More >>

  • Jan 07, 2015 

    Novavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference - 

    GAITHERSBURG, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 11:30 a.m. PT in San Francisco, CA at The Westin St. Francis Hotel. A live webcast link for the present... More >>